CureMatch
×
  • Physicians
    • Patients
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact

Pediatric Cancer Through A Precision Medicine Perspective

Pediatric Cancer Through A Precision Medicine Perspective
Blog PostsResearch

Despite the fact that pediatric cancer death rates have decreased and survival rates increased over the past decades as a result of major advances in cancer treatment, cancer continues to remain a leading cause of death among children.

According to the National Cancer Institute, in 2017, an estimate of 10,270 new cases of pediatric cancer will be diagnosed in the United States. The most common types of cancers diagnoses being: leukemia, brain and spinal cord tumors, lymphomas, and sarcomas. An estimate of 1,190 children is expected to die this year from this disease. [1]

The exact causes of what leads to pediatric cancer still remain unclear but continuous research efforts have made us exceptionally good at finding new information and novel methods of treatment; and while we might not know everything we know enough to continue the fight against pediatric cancer.

So here is what we know about pediatric cancer

Pediatric cancers are not the same as adult cancers

Both, pediatric and adult cancers arise from genetic mutations that lead to an uncontrollable growth of cells that are not “healthy”, thus, threatening the normal function of the body.

How far it spreads and how it is treated is dependent on the type of cancer, and the types of cancer that affect children are different from those that affect adults.

Biologically, cancers in children are different from those in adults primarily due to the type of cell from which it originates.

Adult cancers, such as breast, lung, and colorectal cancer, more often than not develop from epithelial tissue- cells that cover or line bodily surfaces and cavities. Conversely, pediatric cancers, including sarcomas and leukemia, develop often from immature pluripotent cells constituting non-ectodermal tissues such as bone marrow, lymph glands, bone, brain nerves, and muscle. [2]

In addition, the driving mechanisms are simpler. Pediatric cancers have fewer mutations instead of the dozens that may be present in adult cancers. These mutations almost exclusively occur in rapidly dividing tissues and greatly disrupt cell functions.

Pediatric cancers are more likely to develop due to genetics- inherited mutations passed from the parent to the child- or acquired during fetal development events. In contrast, adult cancers typically result from an accumulation of mutations that, in combination with external factors such as smoking or sun overexposure, later cause disease.

Children are not treated the same way as adults

Most adult cancers grow slowly enough that they can be monitored periodically, but pediatric cancers proliferate at terrifying speeds because of the tissues in which they develop. For this reason, when compared to adults, cancer is usually found at an advanced stage in children and require an immediate course of action.

Treating pediatric cancer shares some similarities to treating adult cancer. Chemotherapy, radiation therapy, immunotherapy, surgery, and stem cell transplants are still available and widely used methods of treatment for both categories of patients. But, considering that children’s bodies are unique and biologically different from adults (lung, liver or kidney functions are not considered fully mature until 15 years of age) some treatments or medicines for adults cannot be given to them; therefore, the amount of treatment available is limited, the type of treatment and the dosage need to be tailored to a more personal level.

Precision medicine as a novel treatment for pediatric cancers

The use of surgery, chemotherapy, and radiation therapy are still considered standard treatments for pediatric cancer.  This is simply because they are effective at targeting cancers that arise in rapidly proliferating tissue, so by putting an abrupt stop to the rapid cell growth, we can observe a fast response and in a striking fashion. But, while the use of this standard treatments if effective at meeting the needs of an estimated 80% of children, there is still 20% of children with unique cancer characteristics.

By adopting a “precision medicine” approach in the area of pediatric cancer, we may attempt to identify a targeted therapy option for the remaining 20% of patients whose needs are unmet using standard cancer treatments and at the same time reduce the risk of treatment resistance and long-term deleterious effects.

Months or years after successful treatment completion severe side effects have been observed in pediatric cancer survivors: damage to organs such as the heart and lungs, stunted growth and development, infertility, and an increased risk of secondary cancers are the consequences of standard cancer treatments. [3]

The idea of precision medicine is not a new concept in pediatric oncology, but is not fully embraced. Genomic testing is already done to diagnose and assess many pediatric cancers. This is helpful in determining and designing treatment personalized treatments, but it sometimes may not be enough. A comprehensive dataset developed by a multi-institutional team, including the Dana-Farber/Boston Children’s Cancer and the Blood Disorders Center have helped provided further insight to the fight against cancer and where precision medicine stands in the matter.

The dataset, containing genomic profiles of known and previously-unknown gene mutations across six types and 49 subtypes of pediatric tumors, reveals that all tumors in a subtype do not always arise from the exact same genetic mutations. [4] This makes heterogeneity highlights the need for a higher level of treatment customization.

Because developing new regimens that will benefit patients with unique molecular profiles is constrictive- due to the lack of time knowledge, and resources- the idea of embracing personalized combination therapy of existing drugs appears more enticing. By creating a unique combination of treatment modalities that work synergistically, we are able to target each unique abnormality from a different angle and with a distinct and more appropriate mechanism of action. Personalized combination therapy then results in the ability to give an optimal dose and reduce long-term

and toxic side-effects while greatly improving a child’s quality of life.

Challenges to precision medicine in the area of pediatric cancer

Still, the embrace of precision medicine in pediatric cancer has been slow and challenging.

Until now, researching actionable targets in adult tumors have been the focal point of most pharmaceutical efforts. But pediatric cancer patients rarely benefit from these discoveries due to the limited overlap of genetic abnormalities occurring in adult tumors.

In addition, pediatric cancers have been observed to have fewer mutated genes compared to adult cancers, as a result, researchers have generally few genes to focus on, making targetable mutations in pediatric cancers rare.

A small number of patients and safety concerns in young children have been a challenge as well.

Pediatric cancer is rare- accounting for 1% of all cancers diagnosed. The small number of patients creates for a small population to study, a result, only a small subset of the potential drug will ever be studied. Currently, few targeted drugs are available to children in either approved or experimental form, and with the limited number of clinical trials, gathering critical information, such as age requirements, appropriate formulations, safety, and effectivity, comes to a crawling pace.

Fortunately, from the start, pediatric oncologists have created a culture of collaboration and sharing. Thanks to the sharing of information a larger number of researchers are able to contribute with new insights, insights that increase our knowledge and equips us with the necessary weapons in the fight against cancer.

pediatric-cancer-infographic

CureMatch takes pediatric cancer seriously

For CureMatch, children are the ones with the most life to lose and so we take this matter seriously.

We are working hard to provide a decision support system to guide clinicians, oncologists and pediatric cancer teams around the globe to the most effective combination therapy regimens.

Treatment begins with genetic testing of the tumor and through analytics, our database then sifts through all possible options to determine the most effective regimen personalized for each individual patient.

In joining the fight against pediatric cancer CureMatch offers this personalized service free of charge to children.

Author: Luis Pablos

REFERENCES

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians 2017; 67(1):7-30.

[2] Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board; Hewitt M, Weiner SL, Simone JV, editors. Childhood Cancer Survivorship: Improving Care and Quality of Life. Washington (DC): National Academies Press (US); 2003. The Epidemiology of Childhood Cancer.

[3] Childhood Cancers. NIH. https://www.cancer.gov/types/childhood-cancers

[4] Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Katherine A. Janeway et al. Res January 9 2017 DOI: 10.1158/0008-5472.CAN-16-1106

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

  • Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™

    PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...

  • How Precision Medicine Can Help You

    Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...

  • 64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19

    Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Validation

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

  • CureMatch at WIN Symposium 2018 Winning the War against Cancer with Precision Oncology

    SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results...

  • Personalized Drug Combinations Can Lead to Better Results for Cancer Patients

    A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle...

Archives

  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (619) 277-4761

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer Dec 15

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials Dec 13

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy Oct 19

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
FAQ | Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data